Institut de Myologie, France Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2014
NCT02310906
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Institut de Myologie, France

Active Ingredients

Drugs in Phase 2 Trials (1)

golodirsen (Vyondys 53) (1 trial)

Drugs in Other Trials (1)

levodopa (larodopa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2